Stock Track | 4DMedical Soars 8.32% Intraday on TGA Approval for CT:VQ Imaging Software

Stock Track
Jun 26

4DMedical Ltd's stock soared 8.32% intraday on Friday following a significant regulatory milestone for the company's flagship technology.

The surge comes after the company announced it received Therapeutic Goods Administration (TGA) approval and inclusion on the Australian Register of Therapeutic Goods for its non-contrast ventilation-perfusion imaging software, CT:VQ. This approval enables the commercial use of the technology across Australia.

CT:VQ derives regional lung function information from standard CT scans without the need for injections or contrast agents. The company stated it will now seek Medicare reimbursement through the Medical Services Advisory Committee, which could facilitate broader adoption in healthcare settings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10